Cytokinetics
46
5
6
30
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 55/100
19.6%
9 terminated/withdrawn out of 46 trials
76.9%
-9.6% vs industry average
26%
12 trials in Phase 3/4
73%
22 of 30 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (46)
Study With Omecamtiv Mecarbil (CK-1827452) to Treat Chronic Heart Failure With Severely Reduced Ejection Fraction
Role: lead
Phase 3 Trial to Evaluate the Efficacy and Safety of Aficamten Compared to Metoprolol Succinate in Adults With Symptomatic oHCM
Role: lead
AMBER-HFpEF: Assessment of CK-4021586 in a Multi-Center, Blinded Evaluation of Safety and Tolerability Results in HFpEF
Role: lead
Mavacamten to Aficamten Transition in Patients With Obstructive Hypertrophic Cardiomyopathy
Role: collaborator
A Study to Evaluate the Effect of Aficamten in Pediatric Patients With Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM).
Role: lead
HCMR Re-Imaging Study
Role: collaborator
Phase 3 Trial to Evaluate the Efficacy and Safety of Aficamten Compared to Placebo in Adults With Symptomatic oHCM
Role: lead
Dose-finding Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of CK-3773274 in Adults With Hypertrophic Cardiomyopathy
Role: lead
Phase 3 Trial to Evaluate the Efficacy and Safety of Aficamten Compared to Placebo in Adults With Symptomatic nHCM
Role: lead
Open-label Extension Study to Evaluate the Long-term Safety and Tolerability of Aficamten in Adults With HCM
Role: lead
A Single and Multiple Ascending Dose Study of CK-4021586 in Healthy Adult Participants
Role: lead
Study to Assess the Effect of Omecamtiv Mecarbil (OM) on QT/QTc Intervals in Healthy Adults
Role: lead
Safety, Tolerability and Pharmacokinetics Study of CK-3773274
Role: collaborator
A Single and Multiple Ascending Dose Study of CK-3773274 in Healthy Adult Subjects
Role: lead
A Study to Evaluate the Efficacy and Safety of Reldesemtiv in Patients With Amyotrophic Lateral Sclerosis (ALS)
Role: lead
A Study to Assess the Effect of CK-2127107 on Physical Function in Subjects With Chronic Obstructive Pulmonary Disease
Role: collaborator
A Study to Assess the Anti-fatigability Effect of CK-2127107 in Elderly Male and Female Subjects With Limitations in Mobility
Role: collaborator
A Single and Multiple Ascending Dose Study of CK-3828136 in Healthy Adult Participants
Role: lead
A Phase 3, Open-Label Extension of COURAGE-ALS (CY 5031)
Role: lead
Study to Evaluate the Effect of Aficamten Administration on QT/QTc Interval
Role: lead